RLMD — Relmada Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $120.70m
- $24.37m
- 25
- 24
- 77
- 37
2019 June 30th | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 16.5 | 60.8 | 126 | 161 | 104 |
Operating Profit | -16.5 | -60.8 | -126 | -161 | -104 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17.3 | -59.5 | -126 | -157 | -98.8 |
Net Income After Taxes | -17.3 | -59.5 | -126 | -157 | -98.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -17.3 | -59.5 | -126 | -157 | -98.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -17.3 | -59.5 | -126 | -157 | -98.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.15 | -3.81 | -7.16 | -5.3 | -3.28 |